Omega-3 oil and bone health

Phase 2

Completed

• Conditions: Osteopenia; Musculoskeletal - Osteoporosis

• Registration Number: ACTRN12609000238279
• Lead Sponsor: The Royal Australian College of General Practitioners (RACGP)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2009-05-11
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

DEXA BMD T-score between -1.0 and -2.4 (inclusive)

abbreviations as noted above: Bone Mineral density (BMD); Dual Energy X-ray Absorptiometry (DEXA)

Exclusion Criteria

already on antiresorptive agents

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bone mineral density (BMD) as measured by Dual Energy X-ray Absorptiometry (DEXA) at entry into study and after 1 year of participation. DEXA is measured by a form of x-ray machine which uses software to compare absorption of 2 different energies of radiation, thus deriving a Bone Mineral Density value in g/cm2[1 year from commencement of treatment];change in bone turnover markers as measured by serum N-terminal collagen telopeptide (CTX)[1 year from commencement of treatment]

Secondary Outcome Measures

Name	Time	Method
one[not applicable]